Format

Send to

Choose Destination
Expert Opin Drug Metab Toxicol. 2011 Jan;7(1):1-8. doi: 10.1517/17425255.2011.539201. Epub 2010 Nov 30.

Advances in paediatric pharmacokinetics.

Author information

1
University of Leiden, Leiden/Amsterdam Center for Drug Research, Division of Pharmacology, Leiden, The Netherlands. c.knibbe@antoniusziekenhuis.nl

Abstract

IMPORTANCE OF THE FIELD:

In recent years, interest in paediatric pharmacokinetics has grown. Even though pharmacokinetic and pharmacodynamic relations determine together the optimal drug dose, age-related changes in pharmacokinetics have proven of utmost importance for optimising drug dosing in children.

AREAS COVERED IN THIS REVIEW:

Constraints in paediatric studies result in data sets with specific characteristics requiring advanced analysis and validation approaches which are discussed in conjunction with directions for future research.

WHAT THE READER WILL GAIN:

Advances have been made in the development of descriptive paediatric pharmacokinetic models for specific drugs and age ranges, and in the identification of analysis and diagnostic tools for paediatric model building and evaluation, while sharing of data between academia and/or industry has proven crucial for limiting additional burden in children. Even though progress is being made, currently none of the scaling approaches has proven of universal value for extrapolations to other age ranges and/or other drugs.

TAKE HOME MESSAGE:

The focus of future research should be on the development of mechanistic and validated pharmacokinetic models for specific elimination routes that have predictive and extrapolation potential, making them of use in designing algorithms to derive first-time-in-child doses and individualised dosing guidelines in paediatrics.

PMID:
21117982
DOI:
10.1517/17425255.2011.539201
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center